lesogaberan lesogaberan lesogaberan (azd-3355) was an experimental drug candidate developed by astrazeneca for the treatment of gastroesophageal reflux disease (gerd). as a gabab receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of gerd. lesogaberan names preferred iupac name phosphinic acid other names azd-3355 identifiers cas number 344413-67-8 y= y 3d model (jsmol) interactive image chembl chembl448343 n chemspider 23254384 n echa infocard 100.133.162 iuphar/bps 7705 pubchem cid 9833984 unii 4d6q6hgc7z y comptox dashboard (epa) dtxsid20188011 inchi inchi=1s/c3h9fno2p/c4-3(1-5)2-8(6)7/h3,8h,1-2,5h2,(h,6,7)/t3-/m1/s1 nkey: ljnuieqatdyxjh-gsvougtgsa-n ninchi=1/c3h9fno2p/c4-3(1-5)2-8(6)7/h3,8h,1-2,5h2,(h,6,7)/t3-/m1/s1key: ljnuieqatdyxjh-gsvougtgbq smiles o=(o)c(f)cn properties chemical formula c3h9fno2p molar mass 141.082 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references